Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care

Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care (CIC) - Electronic Measurement of Compliance

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01105325

Acronym

SCAVANCE

Enrollment

1000

Registered

2010-04-16

Start date

2010-04-30

Completion date

2011-03-31

Last updated

2010-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

acute coronary syndrome, treatment compliance, cardiac intensive care unit, secondary prevention, cardiac intensive care unit (CIC), compliance, intensive care

Brief summary

To study compliance with secondary prevention during the first months following discharge from the cardiac intensive care unit (CIC) of patients experiencing a first episode of acute coronary syndrome : quantitative compliance over 3 months with the two principal treatments of the prescription (a statin - rosuvastatin, Crestor® and a platelet aggregation inhibitor - clopidogrel, Plavix®), using an electronic measure system (intelligent blister pack®);

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient admitted to the CIC unit for a first episode of acute coronary syndrome, in whom the CIC cardiologist considers that Crestor® -rosuvastatin is the most appropriate statin, in combination with a platelet aggregation inhibitor (Plavix®-clopidogrel) * Patient giving his/her oral consent to participate in the study. * Patient not previously treated by a lipid-lowering drug.

Exclusion criteria

* Patient with a known history of coronary heart disease. * Patient whose treatment on discharge comprises only one of the two study treatments * Patient participating or who has participated in the previous 3 months in a biomedical research study in cardiology.

Design outcomes

Primary

Measure	Time frame
To measure, using an electronic system (intelligent blister pack®), the duration of treatment and number of treatment intake per day over 3 months with statin and oral antiplatelet therapy following an inaugural acute coronary syndrome.	3 months / every day

Secondary

Measure	Time frame
Analysis of the duration of treatment and number of treatment intake per day at 1 month and 2 months with a statin and a platelet aggregation inhibitor, using an electronic system (intelligent blister pack®).	1 and 2 months / every day
Describe global compliance with the entire prescription over 6 months	6 months / Once at 6 months follow-up
Determine the factors influencing compliance with treatment on discharge from CIC (discharge treatment including a statin - rosuvastatin, Crestor® and a platelet aggregation inhibitor - clopidogrel, Plavix®).	6 months

Countries

France

Outcome results